

Appendix 1 (as supplied by the authors): Treatment procedures for hepatocellular carcinoma (HCC) and relative survival in patients with HCC

Table A1. Treatment procedures for persons diagnosed with hepatocellular carcinoma

	CCP code	CCI code	OHIP code
<i>Potentially curative therapy</i>			
Local excision or destruction of lesion or tissue of liver	62.1		
Partial hepatectomy	62.12		
Other destruction of lesion of liver	62.19		
Lobectomy of liver	62.20		
Excision partial, liver using endoscopic (laparoscopic) approach		10A87DA	
Excision partial, liver using open approach		10A87LA	
Excision partial, liver using ultrasonic aspirator device (for dissection) and open approach		10A87LAAZ	
Liver excision-complete left/right lobectomy			S267
Liver excision-of lesion			S269
Liver excision-hepatectomy left lateral segmental excision			S270
Liver excision-extended right lobectomy			S271
Liver excision-partial lobectomy			S275
Total hepatectomy	62.3		
Liver transplant	62.4		
Auxiliary liver transplant	62.41		
Other transplant of liver	62.49		
Transplant, liver of a deceased donor full size liver		10A85LAXXX	
Transplant, liver of a deceased donor multi organ liver with intestine/pancreas/spleen/stomach (or any combination of)		10A85VCXXX	
Transplant, liver of a living donor split liver		10A85WLXXJ	
Transplant, liver of a deceased donor split liver (or reduced paediatric-size liver)		10A85WLXXX	
Living donor orthotopic liver transplantation recipient			S266
Liver excision-liver transplant-recipient			S294
Digestive system-liver-repeat liver transplant			S295
Destruction, liver endoscopic (laparoscopic) approach using radiofrequency		10A59DAAW	
Destruction, liver percutaneous approach using radiofrequency		10A59HAAW	
Destruction, liver open approach using radiofrequency		10A59LAAW	

Radiofrequency ablation	J069
<i>Non-curative therapy</i>	
Percutaneous ablation	
Destruction, liver endoscopic (abdominal) approach using cryoprobe	10A59DAAD
Destruction, liver endoscopic (abdominal) approach using laser	10A59DAAG
Destruction, liver endoscopic (abdominal) approach using device NEC	10A59DAGX
Destruction, liver endoscopic (abdominal) approach using chemical cautery agent (e.g. ethanol)	10A59DAX7
Destruction, liver percutaneous approach using chemical cautery agent (e.g. ethanol)	10A59HAX7
Destruction, liver open approach using cryoprobe	10A59LAAD
Destruction, liver open approach using laser	10A59LAAG
Destruction, liver open approach using device NEC	10A59LAGX
Destruction, liver open approach using chemical cautery agent (e.g. ethanol)	10A59LAX7
Chemotherapy	
Diagnostic and therapeutic injection(s)/infusion(s) test dose (bleomycin&l-asparaginase once per patient per drug)	G075
Diagnostic and therapeutic injection/infusion-intravenous chemotherapy- each additional injection to	G281
Single agent intravenous chemotherapy i.e. doxorubicin, daunorubicin, epirubicin, mitoxintrone, cisplatin or bleomycin (greater than 10 units per metre square)	G339
Taxol, rituximab, trastuzumab, bortezomib, docetaxel administration or multiple agent intravenous chemotherapy including at least one of either doxorubicin, daunorubicin, epirubicin, mitoxintrone, cisplatin or bleomycin (greater than 10 units per metre square)	G345
Special single agent chemotherapy utilizing either high-dose methotrexate with folinic acid rescue - methotrexate given in a dose of greater than 1 g/m2, high dose cisplatin greater than 75 mg/m2 given concurrently with hydration and osmotic diuresis, high dose cytosine, arabinoside (greater than 2g/m2), or high dose cyclophosphamide (greater than 1g/m2)	G359
Single injection (for agents other than doxorubicin, cisplatin, bleomycin or high dose methotrexate)	G381
Supervision of chemotherapy (marrow suppressant) for malignant or autoimmune disease by telephone - monthly	G382
Arteries-cannulation-chemotherapy-hepatic (TACE)	R776

Supportive/Palliative care

General/Family Practice special palliative care consultation	A945
Special palliative care consultation hospital in patient	C945
Palliative care	C982
Palliative care support individual care 1/2 hr. or major part	K023

CCI, Canadian Classification of Health Interventions – is the new national standard for classifying health care procedures. CCI is the companion classification system to ICD-10-CA. CCI replaces the Canadian Classification of Diagnostic, Therapeutic and Surgical Procedures (CCP) and the intervention portion of ICD-9-CM in Canada. CCP was originally developed by Statistics Canada in 1978 to meet Canadian needs for a procedural classification to be used in conjunction with ICD-9. The Ontario Health Insurance Plan (OHIP), physician billing claims dataset contains service and diagnosis information for outpatient visits in Ontario.

Table A2. Relative survival after diagnosis of hepatocellular carcinoma by sex, year of diagnosis, and age at diagnosis: Sensitivity analysis, merging age at diagnosis 70-79 and ≥ 80 years

Year of Diagnosis	Age at Diagnosis (years)	Cases (N)	Events (N)	1-year Relative Survival % (95% CI)	5-year Relative Survival % (95% CI)
Cohort Analysis					
Female					
1990-1994	< 60	62	48	38.27 (27.09, 49.35)	17.44 (9.45, 27.48)
	60-69	57	45	28.97 (18.74, 40.01)	11.01 (4.92, 19.95)
	≥ 70	58	54	11.85 (6.62, 18.78)	0.03 (0.00, 0.42)
1995-1999	< 60	56	29	49.19 (36.10, 61.04)	25.92 (15.10, 38.17)
	60-69	73	42	54.51 (43.21, 64.52)	19.28 (11.28, 28.99)
	≥ 70	100	80	23.09 (16.59, 30.27)	6.97 (3.12, 13.11)
2000-2004	< 60	77	45	51.77 (40.65, 61.79)	20.44 (11.90, 30.62)
	60-69	102	65	42.00 (32.85, 50.89)	17.61 (10.75, 25.94)
	≥ 70	173	127	46.16 (38.61, 53.43)	10.12 (5.85, 15.86)
2005-2009	< 60	125	47	70.93 (62.18, 78.03)	27.69 (18.27, 37.93)
	60-69	113	63	54.27 (44.83, 62.80)	19.36 (11.87, 28.29)
	≥ 70	237	164	47.60 (41.17, 53.81)	10.00 (5.92, 15.44)
Male					
1990-1994	< 60	167	120	31.81 (25.52, 38.27)	7.13 (3.84, 11.80)
	60-69	213	165	28.08 (23.00, 33.37)	10.56 (7.04, 14.93)
	≥ 70	161	142	18.61 (13.7, 24.16)	4.15 (1.73, 8.38)
1995-1999	< 60	262	175	35.82 (30.62, 41.05)	15.14 (11.14, 19.71)
	60-69	266	191	34.53 (29.32, 39.80)	12.61 (8.90, 17.04)
	≥ 70	292	218	32.29 (27.54, 37.15)	10.26 (6.93, 14.43)
2000-2004	< 60	468	239	52.47 (48.07, 56.67)	27.53 (23.33, 31.89)
	60-69	349	234	43.98 (38.92, 48.94)	17.33 (13.40, 21.71)
	≥ 70	412	280	44.41 (39.74, 49.01)	11.64 (8.48, 15.41)
2005-2009	< 60	683	373	56.94 (53.20, 60.50)	25.13 (21.39, 29.04)
	60-69	479	269	52.68 (48.26, 56.91)	22.85 (18.76, 27.22)
	≥ 70	660	439	51.72 (47.8, 55.52)	14.35 (11.17, 17.98)

CI, confidence intervals.